Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results
Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...
Business Insider16h
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel
In 2024, we established a license and research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify novel targets for inflammatory diseases. In 2021, we entered into ...
Yahoo Finance3h
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechnology company focused on gastrointestinal diseases that was acquired by Merck for $10.8 billion in 2023. Prior ...
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...
PR Newswire8h
Genomics Market to Hit USD 66.85 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™
Based on offerings, the genomics market is divided into product and service segments. The product segment accounted for the ...